Ovagen 20 mg – 10 vials

Ovagen (also known as AC-3 or EDL) is a synthetic tripeptide research compound with the amino acid sequence Glu-Asp-Leu (glutamic acid–aspartic acid–leucine), developed as a Khavinson-style bioregulator primarily targeting hepatic (liver) and gastrointestinal tissues. It functions as an epigenetic regulator that interacts with promoter regions of genes in hepatocytes and epithelial cells, promoting complementary DNA-peptide interactions to normalize protein synthesis, enhance cellular repair mechanisms, and support antioxidant defense pathways. In preclinical models (including toxin-exposed rat livers, aging cell cultures, and hepatic injury studies), Ovagen demonstrates hepatoprotective and cytoprotective effects by reducing oxidative stress markers, mitigating cellular necrosis and inflammation, preserving histological liver structure, normalizing enzyme levels, stimulating regeneration (e.g., via increased proliferative markers), and limiting fibrosis progression. It also shows potential geroprotective actions on aging renal cells and broader support for gastrointestinal mucosal integrity against adverse factors (e.g., toxins, chemotherapy, radiation, or age-related decline). Compared to natural liver extracts, its ultrashort structure provides high stability, bioavailability, and targeted epigenetic modulation without notable adverse effects. Ovagen is utilized in research to investigate mechanisms of liver detoxification, hepatocellular regeneration, gene expression control in metabolic tissues, protective strategies against hepatotoxicity (e.g., from CCl₄, paracetamol, or environmental stressors), gastrointestinal homeostasis, age-related organ decline, preventive approaches for hepatitis, chemotherapy/radiation complications, and the roles of short peptides in epigenetic regulation of cellular resilience, tissue repair, and longevity in hepatic and digestive systems